Buy Recommendation The Australian, page-34

Hey hottod, that James Dunn report appeared on NABtrade today:

Source: nabtrade
Phosphagenics is developing and commercialising innovative human and animal health products using a drug delivery system it invented, called TPM – which stands for both ‘targeted penetration matrix’ and ‘trocopheryl phosphate mixture.’ TPM is a chemical modification of Vitamin E, which can be formulated into gel, patch, cream or spray applications. TPM has been shown to improve delivery of active drugs, both small and large molecules, while reducing potential side effects. TPM is used in both human – both pharmaceutical and consumer care – and animal health markets.
Phosphagenics’ most advanced marketed product is TPM-Diclofenac gel, which is now licensed in 21 countries, through Novartis and Themis Medicare. The Vital ET biofunctional ingredient marketed by Ashland – used in the pre-treatment/skin health phase for products to treat acne – has been going since 2003: Phosphagenics manufactures Vital ET at its manufacturing plant in Australia, while Ashland distributes the product into the North American, European, Asian and South American markets.
In August, Phosphagenics signed a partnership with Terumo, one of Japan’s largest healthcare companies, for a R&D/commercialisation support deal for using TPM with the opiate painkiller Oxymorphone. Phase 1 clinical trials are expected to be activated by August 2018.
Phosphagenics’ consumer personal care and protection business works with global skincare brands: the company selects the most powerful active ingredients available to the skincare industry, and then delivers them into the skin to where they are needed most, using the TPM delivery technology. Phosphagenics’ scientists have developed a range of breakthrough anti-aging, anti-cellulite, anti-stretchmark products, which it licenses to major consumer health companies. The company says the consumer personal care and protection business is generating positive cashflow.
​